介入放射学成本研究系统综述更新:2016年共识小组后续分析
该研究系统回顾了2016年12月至2022年7月间发表的成人及儿童介入放射学成本研究,共纳入62项,多数来自美国。成本效益分析显示介入治疗在肝细胞癌、肾肿瘤、良性前列腺增生、子宫肌瘤、蛛网膜下腔出血和卒中中均比非介入治疗更具成本效益,但方法学异质性大,部分服务领域缺乏研究。
要点
- 介入肿瘤学是成本研究最多的领域,但静脉血栓栓塞、胆道及内分泌介入治疗无相关研究。
- 介入治疗在多项适应症中成本效益优于非介入治疗,但支付意愿阈值未统一。
- 一次性耗材成本在介入总成本中占比高,胸导管栓塞达68%,射频消融42%,化疗栓塞30%,放射栓塞80%,静脉畸形75%。
英文原文(摘要)· 点击展开
PURPOSE: To systematically review cost research in interventional radiology (IR) published since the Society of Interventional Radiology Research Consensus Panel on Cost in December 2016.
MATERIALS AND METHODS: A retrospective assessment of cost research in adult and pediatric IR since December 2016 to July 2022 was conducted. All cost methodologies, service lines, and IR modalities were screened. Analyses were reported in a standardized fashion to include service lines, comparators, cost variables, analytical processes, and databases used.
RESULTS: There were 62 studies published, with most from the United States (58%). Incremental cost-effectiveness ratio, quality-adjusted life-years, and time-driven activity-based costing (TDABC) analyses were performed in 50%, 48%, and 10%, respectively. The most frequently reported service line was interventional oncology (21%). No studies on venous thromboembolism, biliary, or IR endocrine therapies were found. Cost reporting was heterogeneous owing to varying cost variables, databases, time horizons, and willingness-to-pay (WTP) thresholds. IR therapies were more cost-effective than their non-IR counterparts for treating hepatocellular carcinoma ($55,925 vs $211,286), renal tumors ($12,435 vs $19,399), benign prostatic hyperplasia ($6,464 vs $9,221), uterine fibroids ($3,772 vs $6,318), subarachnoid hemorrhage ($1,923 vs $4,343), and stroke ($551,159 vs $577,181). TDABC identified disposable costs contributing most to total IR costs: thoracic duct embolization (68%), ablation (42%), chemoembolization (30%), radioembolization (80%), and venous malformations (75%).
CONCLUSIONS: Although much of the contemporary cost-based research in IR aligned with the recommendations by the Research Consensus Panel, gaps remained in service lines, standardization of methodology, and addressing high disposable costs. Future steps include tailoring WTP thresholds to nation and health systems, cost-effective pricing for disposables, and standardizing cost sourcing methodology.
引用
- Bulman, Malik, Lindquester, et al. Research Consensus Panel Follow-Up: A Systematic Review and Update on Cost Research in IR. J Vasc Interv Radiol. 2023. PMID: 36898665. doi:10.1016/j.jvir.2023.03.001
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。